The Evolving Role of Statins in Hematopoietic Stem and Progenitor Cell Transplantation

Overview

Journal Am J Blood Res

Specialty Hematology

Date 2012 Mar 21

PMID 22432066

Authors

Mehdi Hamadani

Michael D Craig

Laura F Gibson

Scot C Remick

Affiliations

Soon will be listed here.

Abstract

Allogeneic hematopoietic stem cell transplantation is the sole curative modality for a variety of malignant and benign hematological disorders. Despite advances in supportive care and transplant conditioning regimens graft-versus-host disease (GVHD), infectious complications and end organ toxicity remain the leading causes of transplant related mortality (TRM). Development of safe and effective strategies to mitigate these significant complications associated with HSCT, are urgently needed. Statins are lipid lowering drugs, which reduce cholesterol production by inhibiting HMG-CoA reductase, with a well defined toxicity profile. Statins have pleiotropic immunomodulatory effects which are relevant in the context of treating and preventing GVHD. In addition to GVHD statins may possess several other effects that might have clinical benefit in the setting of hematopoietic cell transplantation, such as treatment of bronchiolitis obliterans and antineoplastic activity. Herein we review the emerging role of statins in improving the outcomes of patients undergoing HSCT.

Citing Articles

Fluvastatin Promotes Treg Cell Production in Allogeneic Immune Reaction and Suppresses Inflammatory Response.

Chen X, Huang D, Zhao L, Tang D, Tian Y, Ren C Immun Inflamm Dis. 2025; 13(2):e70165.

PMID: 40007079 PMC: 11861029. DOI: 10.1002/iid3.70165.

References

Leung B, Sattar N, Crilly A, Prach M, McCarey D, Payne H . A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol. 2003; 170(3):1524-30. DOI: 10.4049/jimmunol.170.3.1524. View

Duncan C, Buonanno M, Barry E, Myers K, Peritz D, Lehmann L . Bronchiolitis obliterans following pediatric allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008; 41(11):971-5. DOI: 10.1038/bmt.2008.19. View

Rotta M, Storer B, Storb R, Martin P, Flowers M, Vernon M . Impact of recipient statin treatment on graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2010; 16(10):1463-6. PMC: 2933937. DOI: 10.1016/j.bbmt.2010.05.006. View

Peng X, Jin J, Giri S, Montes M, Sujkowski D, Tang Y . Immunomodulatory effects of 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors, potential therapy for relapsing remitting multiple sclerosis. J Neuroimmunol. 2006; 178(1-2):130-9. DOI: 10.1016/j.jneuroim.2006.06.005. View

Mausner-Fainberg K, Luboshits G, Mor A, Maysel-Auslender S, Rubinstein A, Keren G . The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis. 2007; 197(2):829-39. DOI: 10.1016/j.atherosclerosis.2007.07.031. View

Hamadani M, Hade E, Benson Jr D, Hofmeister C . The effect of statin use at the time of autologous transplant on response and survival in multiple myeloma. Biol Blood Marrow Transplant. 2008; 14(3):351-2. DOI: 10.1016/j.bbmt.2007.12.489. View

Rotta M, Storer B, Storb R, Martin P, Heimfeld S, Peffer A . Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation. Blood. 2009; 115(6):1288-95. PMC: 2826239. DOI: 10.1182/blood-2009-08-240358. View

Krenger W, Snyder K, Byon J, Falzarano G, Ferrara J . Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease. J Immunol. 1995; 155(2):585-93. View

Hazlehurst L, Enkemann S, Beam C, Argilagos R, Painter J, Shain K . Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer Res. 2003; 63(22):7900-6. View

10.

Hamadani M, Hofmeister C, Jansak B, Phillips G, Elder P, Blum W . Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation. Biol Blood Marrow Transplant. 2008; 14(7):783-9. PMC: 4100722. DOI: 10.1016/j.bbmt.2008.04.006. View

11.

Sellner J, Greeve I, Findling O, Kamm C, Minten C, Engelhardt B . Effect of interferon-beta and atorvastatin on Th1/Th2 cytokines in multiple sclerosis. Neurochem Int. 2008; 53(1-2):17-21. DOI: 10.1016/j.neuint.2008.04.004. View

12.

Schmidmaier R, Baumann P, Bumeder I, Meinhardt G, Straka C, Emmerich B . First clinical experience with simvastatin to overcome drug resistance in refractory multiple myeloma. Eur J Haematol. 2007; 79(3):240-3. DOI: 10.1111/j.1600-0609.2007.00902.x. View

13.

Liao J, Laufs U . Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005; 45:89-118. PMC: 2694580. DOI: 10.1146/annurev.pharmtox.45.120403.095748. View

14.

Wagner J, Thompson J, Carter S, Kernan N . Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial. Lancet. 2005; 366(9487):733-41. DOI: 10.1016/S0140-6736(05)66996-6. View

15.

Newman C, Palmer G, Silbershatz H, Szarek M . Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am J Cardiol. 2003; 92(6):670-6. DOI: 10.1016/s0002-9149(03)00820-8. View

16.

Kanda H, Yokota K, Kohno C, Sawada T, Sato K, Yamaguchi M . Effects of low-dosage simvastatin on rheumatoid arthritis through reduction of Th1/Th2 and CD4/CD8 ratios. Mod Rheumatol. 2007; 17(5):364-8. DOI: 10.1007/s10165-007-0589-4. View

17.

Edinger M, Hoffmann P, Ermann J, Drago K, Fathman C, Strober S . CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003; 9(9):1144-50. DOI: 10.1038/nm915. View

18.

Dunn S, Youssef S, Goldstein M, Prodhomme T, Weber M, Zamvil S . Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J Exp Med. 2006; 203(2):401-12. PMC: 2118212. DOI: 10.1084/jem.20051129. View

19.

Youssef S, Stuve O, Patarroyo J, Ruiz P, Radosevich J, Hur E . The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 2002; 420(6911):78-84. DOI: 10.1038/nature01158. View

20.

Lee S, Klar N, Weeks J, Antin J . Predicting costs of stem-cell transplantation. J Clin Oncol. 2000; 18(1):64-71. DOI: 10.1200/JCO.2000.18.1.64. View